Patterns of Dosage changes with transdermal buprenorphine and transdermal fentanyl for the treatment of noncancer and cancer pain: A retrospective data analysis in Germany

Clinical Therapeutics

Volumn 28, Issue 8, 2006, Pages 1144-1154

  Sittl, Reinhard ^a   Nuijten, Mark ^b   Poulsen Nautrup, Barbara ^c  

^a UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^b ERASMUS UNIVERSITY ROTTERDAM   (Netherlands)

^c GRÜNENTHAL GMBH   (Germany)

Author keywords

buprenorphine; cancer pain; dosage stability; fentanyl; noncancer pain; tolerance; transdermal

Indexed keywords

BUPRENORPHINE; FENTANYL;

ADULT; AGED; ARTICLE; CANCER PAIN; COHORT ANALYSIS; DATA ANALYSIS; DOSE RESPONSE; DRUG TOLERABILITY; FEMALE; GERMANY; HUMAN; LOW BACK PAIN; MAJOR CLINICAL STUDY; MALE; OSTEOARTHRITIS; OSTEOPOROSIS; PAIN; RETROSPECTIVE STUDY; TREATMENT INDICATION; TREATMENT OUTCOME;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; ANALGESICS, OPIOID; BUPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; FEMALE; FENTANYL; HUMANS; MALE; MIDDLE AGED; NEOPLASMS; PAIN; PAIN, INTRACTABLE; RETROSPECTIVE STUDIES;

EID: 33748551075     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2006.08.002     Document Type: Article

References (32)

1. Griessinger N., Sittl R., and Likar R. Transdermal buprenorphine in clinical practice-a post-marketing surveillance study in 13,179 patients. Curr Med Res Opin 21 (2005) 1147-1156
2. Davies J., and McVicar A. Issues in effective pain control. 2: From assessment to management. Intj Palliat Nurs 6 (2000) 162-169
3. Mercadante S., Villari P., Ferrera P., and Casuccio A. Opioid-induced or pain relief-reduced symptoms in advanced cancer patients?. Eur J Pain 10 (2006) 153-159
4. Korte W., de Stoutz N., and Morant R. Day-to-day titration to initiate transdermal fentanyl in patients with cancer pain: Short- and long-term experiences in a prospective study of 39 patients. J Pain Symptom Manage 11 (1996) 139-146
5. Radbruch L., Sabatowski R., Petzke F., et al. Transdermal fentanyl for the management of cancer pain: A survey of 1005 patients. Palliat Med 15 (2001) 309-321
6. Buntin-Mushock C., Phillip L., Moriyama K., and Palmer P.P. Age-dependent opioid escalation in chronic pain patients. Anesth Analg 100 (2005) 1740-1745
7. Sittl R., Nuijten M., and Nautrup B.P. Changes in the prescribed daily doses of transdermal fentanyl and transdermal buprenorphine during treatment of patients with cancer and noncancer pain in Germany: Results of a retrospective cohort study. Clin Ther 27 (2005) 1022-1031
8. Kieffer B.L., and Evans C.J. Opioid tolerance-in search of the Holy Grail. Cell 108 (2002) 587-590
9. Zuo Z. The role of opioid receptor internalization and beta-arrestins in the development of opioid tolerance. Anesth Analg 101 (2005) 728-734
10. Zaki P.A., Keith Jr. D.E., Brine G.A., et al. Ligand-induced changes in surface mu-opioid receptor number: Relationship to G protein activation?. J Pharmacol Exp Ther 292 (2000) 1127-1134
11. Mercadante S. Opioid rotation for cancer pain: Rationale and clinical aspects. Cancer 86 (1999) 1856-1866
12. Moryl N., Santiago-Palma J., Kornick C., et al. Pitfalls of opioid rotation: Substituting another opioid for methadone in patients with cancer pain. Pain 96 (2002) 325-328
13. Milligan K., Lanteri-Minet M., Borchert K., et al. Evaluation of long-term efficacy and safety of transdermal fentanyl in the treatment of chronic noncancer pain. J Pain 2 (2001) 197-204
14. Mystakidou K., Parpa E., Tsilika E., et al. Long-term management of noncancer pain with transdermal therapeutic system-fentanyl. J Pain 4 (2003) 298-306
15. Mystakidou K., Tsilika E., Parpa E., et al. Long-term cancer pain management in morphine pre-treated and opioid naive patients with transdermal fentanyl. Int J Cancer 107 (2003) 486-492
16. Likar R., Kayser H., and Sittl R. Long-term management of chronic pain with transdermal buprenorphine. A mul ticenter, open-label, follow-up study in patients from three short-term clinical trials. Clin Ther 28 (2006) 943-952
17. Zenz M., Strumpf M., and Tryba M. Long-term oral opioid therapy in patients with chronic nonmalignant pain. J Pain Symptom Manage 7 (1992) 69-77
18. Koppert W., Ihmsen H., Korber N., et al. Different profiles of buprenorphineinduced analgesia and antihyperal gesia in a human pain model. Pain 118 (2005) 15-22
19. Dietlein G., and Schroder-Bernhardi D. Use of the Mediplus patient database in healthcare research. Int J Clin Pharmacol Ther 40 (2002) 130-133
20. [EMEA Web site]. European Agency for the Evaluation of Medicinal Products. International Conference on Harmonisation-World Health Organization. Guideline for Good Clinical Practice. Accessed April 15, 2006. ICH Topic E6 (2002), WHO, Geneva, Switzerland. http://www.emea.eu.int. Accessed April 15, 2006
21. Sittl R., Likar R., and Nautrup B.P. Equipotent doses of transdermal fentanyl and transdermal buprenor phine in patients with cancer and noncancer pain: Results of a retrospective cohort study. Clin Ther. 27 (2005) 225-237
22. International Statistical Classification of Diseases and Related Health Problems, 10th Revision (2004). http://www.who.int/icd/vol1htm2003
23. Transtec (transdermal buprenorphine) (2003), Grünenthal GmbH, Aachen, Germany
24. Durogesic (transdermal fentanyl) (2001), Janssen Pharmaceutica, Inc, Titusville, NJ
25. Available at:. European Pharmaceutical Marketing Research Association. Anatomical Classification System. Accessed November 19 (2004). http://www.ephmra.org.
26. World Health Organization Guidelines. Cancer pain relief and palliative care (1990), WHO, Geneva, Switzerland
27. Ackerman S.J., Mordin M., Reblando J., et al. Patient-reported utilization patterns of fentanyl transdermal sys tem and oxycodone hydrochloride controlled-release among patients with chronic nonmalignant pain. J Manag Care Pharm 9 (2003) 223-231
28. Donner B., Zenz M., Strumpf M., and Raber M. Long-term treatment of cancer pain with transdermal fentanyl. J Pain Symptom Manage 15 (1998) 168-175
29. Armitage P., and Berry G. Statistical Methods in Medical Research. 3rd ed. (1994), Blackwell Publishing, Oxford, United Kingdom
30. Gasquet I., Gury C., Tcherny-Lessenot S., et al. Patterns of prescription of four major antipsychotics: A retro spective study based on medical records of psychiatric inpatients. Pharmacoepidemiol Drug Saf 14 (2005) 805-811
31. Motheral B., Brooks J., Clark M.A., et al. A checklist for retrospective database studies-report of the ISPOR Task Force on Retrospective Databases. Value Health 6 (2003) 9097
32. [in German]. Maier C., Schaub C., Willweber-Strumpf A., and Zenz M. Long-term efficacy of opioid medication in patients with chronic non-cancerassociated pain. Results of a survey 5 years after onset of medical treatment. Schmerz 19 (2005) 410-417